Clinical trials · North Carolina
Cancer clinical trials in North Carolina
We’re tracking 622 recruiting cancer studies with a site in North Carolina — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in North Carolina
- NCT06883097Recruiting
Quitting smoking with HIV: A smoking cessation trial
This study tests whether nicotine replacement therapy (like patches or gum) can help people living with HIV quit smoking. You'll be part of a program that supports your quit attempt while you receive care for HIV.
Winston-Salem, North CarolinaAges 18 years+ - NCT06875310RecruitingPhase 3
Study of adagrasib plus pembrolizumab plus chemotherapy for KRAS G12C lung cancer
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
Asheville, North CarolinaAges 18 years+ - NCT06866964RecruitingPhase 2
Aspirin to prevent blood clots in advanced germ cell cancer chemotherapy
This trial tests if daily aspirin can prevent dangerous blood clots in people receiving chemotherapy for advanced testicular or germ cell cancer. It is for those at high risk of clots and aims to improve safety during treatment.
Winston-Salem, North CarolinaAges 18–70 - NCT06841354RecruitingPhase 3
Sac-TMT alone or with pembrolizumab for advanced triple-negative breast cancer
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Garner, North CarolinaAges 18 years+ - NCT06830265Recruiting
Comparing a new biopsy needle to the standard one for prostate cancer
This study tests a new, specially designed biopsy needle system against the standard needle system used for prostate biopsies. The researchers will compare how well each system collects tissue samples from men who have suspicious MRI findings, to see if the new needle might give better results.
Durham, North CarolinaAges 18 years+ - NCT06823167RecruitingPhase 1
Study of IM-1021 for advanced cancers
This trial tests a new drug (IM-1021) for people with advanced cancers like lymphoma or solid tumors who have run out of standard options. The drug targets a protein called ROR1, which is found on some cancer cells, and may help shrink tumors or slow their growth.
Charlotte, North CarolinaAges 18 years+ - NCT06819254RecruitingPhase 4
Fisetin for fatigue in older cancer survivors
This study tests whether a natural compound called fisetin can reduce fatigue in people aged 60+ who have completed cancer treatment. If you still feel tired often, this pill-based treatment might help you regain energy.
Winston-Salem, North CarolinaAges 65 years+ - NCT06807437RecruitingPhase 3
Testing lanreotide before pancreas surgery to prevent leaks
This trial tests if a medicine called lanreotide, given before surgery, can prevent a common complication (pancreatic leak) after removing part of the pancreas. It is for people with pancreatic cancer or a growth that could become cancer who are scheduled for a specific type of pancreas surgery.
Concord, North CarolinaAges 18 years+ - NCT06796907RecruitingPhase 1/Phase 2
Mocertatug rezetecan with other drugs for advanced solid tumors
This trial tests a new drug, mocertatug rezetecan, combined with other anti-cancer therapies for people with advanced solid tumors like endometrial or ovarian cancer. It aims to see if the combination is safe and effective.
Durham, North CarolinaAges 18 years+ - NCT06773936Enrolling by invitationPhase 2
Adding asciminib to usual care for adults with newly diagnosed Ph+ ALL
This trial tests if adding asciminib, a targeted pill, to standard treatment works better for adults newly diagnosed with a specific type of acute lymphoblastic leukemia (Ph+ ALL). It is for those who are older, or who cannot or choose not to have intensive chemotherapy.
Durham, North CarolinaAges 60 years+ - NCT06774131RecruitingPhase 3
Study of UGN-104 for low-grade upper tract urothelial cancer
This trial tests a new treatment called UGN-104 for people with low-grade upper tract urothelial cancer (a type of cancer in the tube that carries urine from the kidney to the bladder). The treatment is given directly into the kidney area to kill cancer cells without surgery.
Charlotte, North CarolinaAges 18 years+ - NCT06767514RecruitingPhase 3
Ivonescimab for first-line treatment of advanced NSCLC with high PD-L1
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
Chapel Hill, North CarolinaAges 18 years+ - NCT06765109RecruitingPhase 3
Testing neladalkib for untreated ALK-positive lung cancer
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
Charlotte, North CarolinaAges 18 years+ - NCT06751329RecruitingPhase 1/Phase 2
Study of DM002 for advanced solid tumors
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
Huntersville, North CarolinaAges 18 years+ - NCT06745908RecruitingPhase 3
New drug combo for lung cancer after immunotherapy stops working
This trial tests a new drug combination (N-803 and tislelizumab with chemotherapy) for people whose lung cancer stopped responding to standard immunotherapy. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
Hickory, North CarolinaAges 18–90 - NCT06706076RecruitingPhase 1/Phase 2
Experimental pill for lung cancer with EGFR or HER2 changes
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
Durham, North CarolinaAges 18 years+ - NCT06697600Recruiting
Supporting decisions for older adults with AML and their caregivers
This study helps older adults with newly diagnosed acute myeloid leukemia (AML) and their caregivers make informed decisions about treatment. You and a caregiver (like a family member or friend) will get extra support to talk through your options.
Chapel Hill, North CarolinaAges 60 years+ - NCT06701812RecruitingPhase 2
Digoxin for relapsed non-WNT non-SHH medulloblastoma
This trial tests whether the drug digoxin can help treat medulloblastoma that has come back after standard treatments like chemotherapy and radiation. Digoxin is a heart medicine being studied for its anticancer effects against a specific type of medulloblastoma.
Charlotte, North CarolinaAges 1–30 - NCT06687603Recruiting
Detecting Barrett's esophagus in people without heartburn
This study aims to screen for Barrett's esophagus in people who are getting a routine colonoscopy but do not have chronic heartburn. It uses a simple, non-invasive cell collection device (EsoCheck) to see if you might have Barrett's esophagus, which can increase the risk of esophageal cancer.
Chapel Hill, North CarolinaAges 50 years+ - NCT06672146RecruitingPhase 2
New treatments for AML with an IDH2 mutation
This trial tests new treatments for people with newly diagnosed acute myeloid leukemia (AML) that has a change in the IDH2 gene. It aims to find a better option for those who cannot have standard high-dose chemotherapy.
Charlotte, North CarolinaAges 18 years+ - NCT06661915RecruitingPhase 2
Combination treatment for advanced myeloproliferative neoplasms
This study tests whether adding a new drug called iadademstat to the standard treatment ASTX727 helps people with advanced myeloproliferative neoplasms (blood cancers that cause the bone marrow to make too many cells). The goal is to see if the combination is safe and works better than the standard treatment alone.
Concord, North CarolinaAges 18 years+ - NCT06662786RecruitingPhase 3
Amivantamab plus chemo vs. standard chemo for left-sided colorectal cancer
This trial compares a new combination (amivantamab plus chemotherapy) with the standard treatment (cetuximab plus chemotherapy) as the first therapy for people with left-sided colorectal cancer that has spread. The goal is to see which approach works better when the tumor has no mutations in the KRAS, NRAS, or BRAF genes.
Chapel Hill, North CarolinaAges 18 years+ - NCT06667076RecruitingPhase 2
Amivantamab combinations for advanced EGFR-mutant lung cancer
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
Winston-Salem, North CarolinaAges 18 years+ - NCT06667908RecruitingPhase 2
Study of a drug with chemoradiation for stage 3 lung cancer
This trial tests a new drug, JNJ-90301900, given together with standard chemotherapy and radiation, followed by maintenance immunotherapy (durvalumab) for people with stage 3 non-small cell lung cancer that cannot be surgically removed. The goal is to see if adding this drug improves outcomes.
Pinehurst, North CarolinaAges 18 years+
Cancer trials by city in North Carolina
Where these studies are running in North Carolina
Institutions with a site for the recruiting cancer studies listed above.
- Duke University Medical Center · 6 studies
- Carolinas Medical Center/Levine Cancer Institute · 3 studies
- University of North Carolina at Chapel Hill · 3 studies
- Atrium Health Cabarrus · 2 studies
- Atrium Health Wake Forest Baptist · 2 studies
- Levine Cancer Institute · 2 studies
- Atrium Health
- Atrium Health Carolinas Medical Center
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in North Carolina?
- Yes. We're currently tracking 622 recruiting cancer studies with a site in North Carolina, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in North Carolina?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in North Carolina to take part?
- Not necessarily. These studies have a site in North Carolina, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in North Carolina regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.